☆ 4.7 Letter

Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients

CRITICAL CARE (2020)

Journal

CRITICAL CARE

Volume 24, Issue 1, Pages -

Publisher

BMC

DOI: 10.1186/s13054-020-03227-4

Keywords

COVID-19; Adverse events; Nafamostat mesylate; Favipiravir

Categories

Critical Care Medicine

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

No Data Available

No Data Available

No Data Available

© Peeref 2019-2024. All rights reserved.